To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.

Inclusion Criteria:

1. Male or female infants or children 16 years of age or younger
2. Patient must be a suitable candidate for conventional 2-port or 3-port pars plana vitrectomy
3. Patient with attached vitreous somewhere in posterior pole
4. Patient's parent or guardian must be willing and able to comply with follow-up requirements
5. Patient's parent(s) must sign informed parental permission form and in the case of school-age children the patient must sign assent form

Exclusion Criteria:

1. Patient diagnosed with Stage 1, 2, 3 or 5 retinopathy of prematurity (ROP) at the time of surgery
2. Unclear media, which precludes assessment of the posterior pole such as a cataract or vitreal opacity
3. Active parental/guardian drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with parent's or guardian's adherence to study requirements
4. Medical problems that make consistent follow-up over the treatment period uncertain.
5. Patient must not have participated in an investigational drug or device study in the prior 30 days
6. Female Patients of childbearing potential must not be pregnant or lactating.

16 eyes randomized and treated (in 15 subjects) with ocriplasmin & 8 eyes randomized and treated (in 8 subjects) with placebo. Randomisation was at the eye not the subject level; in 1 subject, both eyes were randomised to ocriplasmin; in 1 subject, 1 eye was randomised to ocriplasmin & 1 eye randomised to placebo. 22 subjects participated, 24 eyes.

Adverse Events (AEs)/Serious Adverse Events (SAEs) were collected from the study drug administration day to the end of study (6 months follow-up visit).

The reporting for the study was made based in number of eyes and not in the number of participants, therefore the number of "participants" at risk in the AE section is actually the number of "eyes" at risk.